Merck & Co., Inc. (MRK)
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.
Here's Why Merck (MRK) Fell More Than Broader Market
In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.
Merck: Best Case For Option Collars We'll Ever See
I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier this year limited losses compared to straight ownership, demonstrating why I favor this strategy for "dog" stocks. Currently, MRK stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet.
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
Merck's cholesterol drug meets main goal in late-stage studies
Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies.
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
Merck Stock's Ticking Keytruda Time Bomb
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.
